1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69C59DD31F835D43965258314001F1B4E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/9C59DD31F835D43965258314001F1B4E!OpenDocument
18
19OpenDocument
2034.207.82.217
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB






Products & Services >> Best Practice Database >>Archived Research Alerts >>August 2018 Research

AUGUST 2018 Research Alert

This month we added four new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies explore three important areas within pharma: Real World Evidence Generation, Patient Adherence and Combination Products. Two of the new studies involve Real World Evidence Generation; the first RWE study focuses on current and future trends with observational studies while the other RWE study examines the same with non-safety registries studies. The third study explores the strategies and effectiveness measures organizations are using to enhance their Patient Adherence programs. The last study reviews Combination Products and, specifically, external engagement, staffing and budget related to these types of products.

The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.


Download: Understanding the Changing Landscape of Real World Evidence Generation: Observational Studies (5519)

The pharmaceutical industry has been boosting internal RWE capabilities and is increasingly outsourcing to vendors specializing in RWE generation. Best Practices, LLC conducted this study to present benchmarks on the data collection methods used, the level of outsourcing used and valued vendor traits for five RWE study methods: Post-authorization Safety Studies, Drug Utilization Studies, Prospective Observational Studies with HEOR Objectives, Post-authorization Efficacy studies and Medical Record Abstractions.


Download: Understanding the Changing Landscape of Real World Evidence Generation: Non-Safety Registries (5520)

Real World Evidence (RWE) is a key driver of formulary and reimbursement decisions. Best Practices, LLC undertook this study to present current and future trends for four RWE study methods: Disease Registries, Product Registries, Pregnancy Registries, and Vaccine Registries.


Download: Gaining Support for Patient Adherence Programs: Effective Strategies and Measuring Effectiveness (5517)

As pharmaceutical and biotechnology companies focus more on improving patient adherence, organizations are searching for ways to boost the effectiveness of their adherence programs. Best Practices, LLC undertook this research to identify key metrics for measuring adherence program effectiveness, and uses case examples to examine winning approaches for driving adherence.


Download: Leading in the Combination Product Space: Insights for Improving External Engagement (5518)

The successful development and launch of new combination products can provide a significant competitive advantage to biopharmaceutical organizations. Best Practices, LLC undertook this benchmarking research to inform product and leadership teams about key external engagement approaches as well as staffing and investment levels for combination products.